CNTX
Context Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.36
−0.36%Jun 15, 2026, 15:10 UTC
Context Therapeutics released interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T-cell engaging bispecific antibody, in patients with advanced platinum-resistant ovarian cancer.
Source: